Grifols News and Activities
Presence
Grifols develops and supplies plasma medicines, diagnostic products, and hospital pharmacy services. It serves hospitals, clinics, laboratories, and healthcare professionals with treatments and tools for patient care.
Grifols products and services overview:
- Plasma therapies
- Diagnostic systems
- Hospital pharmacy
- Blood collection
- Biopharma services
Revenue: ~$8 billion
Employees: 24,000
Headquarters: Barcelona, Spain
Grifols is one of the...
Grifols is a company listed under the stock ticker GRFS (ES).
Grifols has a direct presence in 5 countries.Grifols has 5 subsidiaries including Alkahest, Biotest and Biotest Austria.
They are in:
- Pharmaceuticals67%
- Biotechnology17%
- Other17%
Executives
View the org chart displaying its 67 main executives
Most searched biographies at Grifols
- Nacho Abia, Chief Executive Officer and Director
- Tomas Daga Gelabert, Director
- Susana González, Independent Director
Popular executive movements at Grifols
- Jörg Schuettrumpf, Chief Scientific Innovation officer, has left the company (posted on April 7 2026).
Create your alert
to follow the executive moves at Grifols.
Pharmaceuticals
Grifols has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Grifols
- Grifols doubles the number of positions in its vocational training program over the past year in Spain
- Grifols increases Q1 2026 revenues by 3-3 to 1-7billion-and net profit 21-9 to 73 million
- Grifols strengthens its position among the world-s most sustainable biotechnology companies after improving its Dow Jones Best-in-Class score
- Living with primary immunodeficiencies the critical role of emotional support
- Grifols streamlines its global plasma network with the closure of 29 donation centers in the US
- Grifols receives FDA approval for its malaria blood screening assay
- GigaGen presents positive phase 1 data on non-blocking anti-CTLA-4 drug candidate GIGA-564 at AACR 2026
- Grifols announces 500m redemption of 7-5 2030 bonds to further optimize its capital structure
- Grifols successfully completes refinancing of 2027 maturities further strengthening balance sheet and extending debt profile
- Grifols fully refinances all 2027 maturities following a significantly upsized euros 3bn Term Loan B
- View more press releases Close
Social media about Grifols
- Grifols on Wikipedia, Google News & Yahoo Finance
- Grifols on LinkedIn, X (Twitter) & YouTube
